茲卡病毒治療市場規模、佔有率和成長分析（按疫苗類型、檢測類型、最終用戶和地區分類）—產業預測（2026-2033 年）

預計到 2024 年，全球茲卡病毒治療市場規模將達到 22.7 億美元，到 2025 年將達到 25.8 億美元，到 2033 年將達到 71.6 億美元，預測期（2026-2033 年）的複合年成長率為 13.6%。

受感染率上升、研發投入增加以及民眾對預防和疫苗接種意識增強的推動，全球茲卡病毒治療市場正經歷強勁成長。寨卡病毒主要透過蚊子傳播，尤其在熱帶和亞熱帶地區，會造成嚴重的先天性畸形和神經病變等重大風險，從而推動市場需求。 mRNA技術和數位化監測框架等技術進步正在加速疫苗研發並提高安全性。此外，各國政府為預防茲卡病毒感染所採取的措施也刺激了市場需求。人工智慧、機器學習、區塊鏈和物聯網等技術在疫苗生產和物流中的應用，透過提高效率、預測疫情爆發、確保分發透明度以及加強公眾對預防和治療策略的教育，正在徹底改變這一領域，最終重塑市場動態。

全球茲卡病毒治療市場促進因素

茲卡病毒感染病例的增加，尤其是在熱帶和亞熱帶地區，是由國際旅行增加、氣候變遷、都市化以及蚊蟲數量成長等因素共同驅動的。這些因素共同導致對有效預防和治療方法寨卡病毒的需求日益迫切。為此，各國政府和國際衛生組織已大幅增加對茲卡病毒預防工作的投入，從而提高了應對這項公共衛生挑戰的治療需求。對茲卡病毒預防的日益重視進一步推動了全球相關治療方法和預防措施市場的成長。

限制全球茲卡病毒治療市場的因素

茲卡病毒治療藥物的研發面臨許多挑戰，主要原因在於上市前大量研究和多項臨床試驗的高成本。不同監管機構的核准標準各不相同，因此需要額外的研究和資金投入才能滿足合規要求。此外，一些候選疫苗需要冷藏和完善的低溫運輸物流，進一步增加了營運成本。這些因素共同構成了茲卡病毒治療藥物發展和廣泛應用的重大障礙，並可能影響整體市場潛力。

全球茲卡病毒治療市場趨勢

全球茲卡病毒治療市場正經歷顯著的發展趨勢，這主要得益於疫苗技術的進步，尤其是mRNA和DNA疫苗平台的出現。這些創新方法能夠更快、更有效率地開發疫苗，使企業能夠迅速回應公共衛生需求。監管機構和醫療機構對這些新技術的支持日益增強，從而促進了寨卡疫苗的市場接受度和普及應用。這一趨勢不僅加速了有效療法的普及，也促進了生物製藥公司、研究機構和政府之間的合作，最終有助於建立應對全球茲卡病毒大流行的強大研發管線。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 一手和二手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

全球茲卡病毒治療市場規模（按疫苗類型和複合年成長率分類）（2026-2033 年）

• 去活化病毒疫苗
• 減毒活病毒疫苗
• DNA疫苗
• mRNA疫苗

全球茲卡病毒治療市場規模（按檢測類型和複合年成長率分類）（2026-2033 年）

• 分子檢測
• 血清學檢測

全球茲卡病毒治療市場規模（依最終用戶分類）及複合年成長率（2026-2033 年）

• 醫院和診所
• 研究所

全球茲卡病毒治療市場規模（依分銷管道分類）及複合年成長率（2026-2033 年）

• 醫院藥房
• 零售藥房
• 網路藥房

全球茲卡病毒治療市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • GCC
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

  主要企業簡介

  • Moderna公司（美國）
  • Valneva SE（法國）
  • Inovio Pharmaceuticals, Inc.（美國）
  • Emergent BioSolutions Inc.（美國）
  • Novavax公司（美國）
  • 強生公司（美國）
  • 輝瑞公司（美國）
  • Bharat BIoTech International Ltd.（印度）
  • GeoVax Labs, Inc.（美國）
  • 武田藥品工業株式會社（日本）
  • 葛蘭素史克公司（GSK）（英國）
  • BioCryst Pharmaceuticals, Inc.（美國）
  • Zydus Cadila（印度）
  • GeneOne生命科學公司（韓國）
  • Kimer Med（西班牙）
  • BioVaxys Technology Corporation（加拿大）
  • Creative Diagnostics（美國）
  • 印度免疫學有限公司（印度）
  • 賽諾菲巴斯德（法國）

結論與建議

Global Zika Virus Therapeutics Market size was valued at USD 2.27 Billion in 2024 and is poised to grow from USD 2.58 Billion in 2025 to USD 7.16 Billion by 2033, growing at a CAGR of 13.6% during the forecast period (2026-2033).

The global Zika virus therapeutics market is experiencing robust growth, driven by rising infection rates, intensified research and development efforts, and heightened public awareness regarding prevention and vaccination. The virus, predominantly transmitted by mosquitoes, poses significant risks including severe birth defects and neurological disorders, particularly in tropical and subtropical areas, thereby fueling demand. Technological advancements such as mRNA technology and digital monitoring frameworks are accelerating vaccine development and enhancing safety. Additionally, government initiatives aimed at Zika prevention are amplifying demand. The integration of AI, machine learning, blockchain, and IoT into vaccine production and logistics is revolutionizing the sector by improving efficiency, forecasting outbreaks, ensuring transparency in distribution, and bolstering public education on prevention and treatment strategies, ultimately reshaping market dynamics.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Zika Virus Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Zika Virus Therapeutics Market Segments Analysis

Global Zika Virus Therapeutics Market is segmented by Vaccine Type, Test Type, End User, Distribution Channel and region. Based on Vaccine Type, the market is segmented into Inactivated Virus Vaccine, Live Attenuated Vaccine, DNA Vaccine and mRNA Vaccine. Based on Test Type, the market is segmented into Molecular Test and Serological Test. Based on End User, the market is segmented into Hospitals and Clinics and Research Institutes. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Zika Virus Therapeutics Market

The rising incidence of Zika virus, especially in tropical and subtropical areas, is being driven by factors such as increased global travel, climate change, urbanization, and a growing mosquito population. These elements collectively heighten the urgency for effective prevention and treatment options for the virus. In response, both governments and international health organizations are significantly increasing their investments in Zika virus prevention efforts, thereby elevating the demand for therapeutics aimed at addressing this public health challenge. This escalating focus on Zika virus control is further stimulating growth in the global market for related treatments and preventive measures.

Restraints in the Global Zika Virus Therapeutics Market

The development of therapeutics for the Zika virus faces significant challenges, primarily driven by the high costs associated with extensive research and multiple clinical trials prior to market introduction. Various regulatory bodies impose differing acceptance criteria, necessitating additional research and financial investment to meet compliance requirements. Furthermore, several of the vaccine candidates demand cold storage and robust cold chain logistics, which further escalates operational expenses. These factors collectively create substantial barriers that could hinder the growth and accessibility of Zika virus therapeutics, impacting the overall market potential.

Market Trends of the Global Zika Virus Therapeutics Market

The Global Zika Virus Therapeutics market is witnessing a significant trend driven by advancements in vaccine technology, particularly the emergence of mRNA and DNA-based platforms. These innovative approaches facilitate quicker and more efficient vaccine development, enabling companies to respond rapidly to public health needs. Regulatory bodies and medical organizations are increasingly endorsing these new technologies, which enhances market acceptance and adoption of Zika vaccines. This trend not only accelerates the availability of effective therapeutics but also fosters collaboration among biopharmaceutical firms, research institutions, and governments, ultimately contributing to a robust pipeline aimed at combatting Zika Virus outbreaks globally.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Zika Virus Therapeutics Market Size by Vaccine Type & CAGR (2026-2033)

• Market Overview
• Inactivated Virus Vaccine
• Live Attenuated Vaccine
• DNA Vaccine
• mRNA Vaccine

Global Zika Virus Therapeutics Market Size by Test Type & CAGR (2026-2033)

• Market Overview
• Molecular Test
• Serological Test

Global Zika Virus Therapeutics Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals and Clinics
• Research Institutes

Global Zika Virus Therapeutics Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Zika Virus Therapeutics Market Size & CAGR (2026-2033)

• North America (Vaccine Type, Test Type, End User, Distribution Channel)
  • US
  • Canada
• Europe (Vaccine Type, Test Type, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Vaccine Type, Test Type, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Vaccine Type, Test Type, End User, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Vaccine Type, Test Type, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Moderna Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Valneva SE (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Inovio Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Emergent BioSolutions Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novavax, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bharat Biotech International Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GeoVax Labs, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (GSK) (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioCryst Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Cadila (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GeneOne Life Science Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kimer Med (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioVaxys Technology Corporation (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Creative Diagnostics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Indian Immunologicals Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi Pasteur (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations